Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of “Hold” from Analysts

Elanco Animal Health Incorporated (NYSE:ELAN) has been given a consensus rating of “Hold” by the eight brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $16.43.

A number of research firms recently commented on ELAN. Barclays lifted their target price on Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. Stifel Nicolaus cut their price objective on shares of Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday. Leerink Partners began coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 target price for the company. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Finally, UBS Group assumed coverage on Elanco Animal Health in a report on Monday, December 9th. They issued a “buy” rating and a $18.00 price objective for the company.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Commerce Bank raised its stake in Elanco Animal Health by 2.2% during the third quarter. Commerce Bank now owns 35,114 shares of the company’s stock worth $516,000 after purchasing an additional 741 shares during the period. HBK Sorce Advisory LLC lifted its holdings in Elanco Animal Health by 9.4% during the 2nd quarter. HBK Sorce Advisory LLC now owns 12,920 shares of the company’s stock worth $186,000 after buying an additional 1,107 shares during the last quarter. Keene & Associates Inc. boosted its position in shares of Elanco Animal Health by 5.7% during the 3rd quarter. Keene & Associates Inc. now owns 22,945 shares of the company’s stock worth $337,000 after acquiring an additional 1,240 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in Elanco Animal Health by 337.7% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after purchasing an additional 1,361 shares in the last quarter. Finally, M&T Bank Corp lifted its holdings in shares of Elanco Animal Health by 5.9% in the 3rd quarter. M&T Bank Corp now owns 26,407 shares of the company’s stock valued at $388,000 after purchasing an additional 1,464 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Down 2.3 %

Shares of NYSE ELAN opened at $11.53 on Friday. Elanco Animal Health has a 12-month low of $11.28 and a 12-month high of $18.80. The stock’s fifty day simple moving average is $12.69 and its two-hundred day simple moving average is $13.54. The stock has a market capitalization of $5.70 billion, a PE ratio of 28.83, a price-to-earnings-growth ratio of 1.96 and a beta of 1.41. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.01. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same period in the prior year, the company posted $0.18 EPS. The firm’s quarterly revenue was down 3.6% compared to the same quarter last year. As a group, analysts expect that Elanco Animal Health will post 0.92 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.